# Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

> **NCT00521781** · PHASE2 · TERMINATED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 14 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Leuprolide
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00521781
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-10
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521781, "Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00521781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*